Reldesemtiv (formely: CK-2127107) is an experimental drug being developed by Cytokinetics as an add-on therapy in spinal muscular atrophy. It is a next-generation fast skeletal muscle troponin activator whose aim is to increase muscle fibre reactivity under the conditions of motor neuron damage.
Clinical trials
As of June 2018, reldesemtiv has successfully completed a phase-2 clinical trial in participants with SMA types 2 and 3.